2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

5678 A single-nucleotide atlas of the epitranscriptome reveals METTL3-dependent therapeutic vulnerabilities in multiple myeloma

Laure Vreux, PhD, Mattia Furlan2, Roberta Torcasio3, Domenico Maisano, PhD4, Tallya Maciel5, Bahar Dakiki Korucu, MD6, Maxime Bellefroid, PhD7, Rosa Alba Parisi8, Anil Aktas-Samur, PhD9, Vanessa Favasuli10, Marcello Turi, PhD11, Paola Rampa12, Michela Cumerlato13, Kushani Shah, PhD14, Mariateresa Fulciniti, PhD15, Kenneth Anderson, MD16, Annamaria Gulla, MD17, Parth Shah, MD18, Mehmet Kemal Samur, PhD19, Nikhil Munshi, MD20, Eugenio Morelli, MD21
1 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
2 INOC, Istituto Nazionale Oncologico Candiolo, IRCCS, Candiolo, Italy
3 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
4 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
5 Dana-Farber Cancer Institute, Boston, United States
6 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States
7 Harvard Medical School, Boston, United States, Massachusetts Institute of Technology, Cambridge, United States, Ragon Institute, Cambridge, United States
8 INOC, Istituto Nazionale Oncologico Candiolo, IRCCS, Candiolo, Italy
9 Dana-Farber Cancer Institute, Boston, United States
10 INOC, Istituto Nazionale Oncologico Candiolo, IRCCS, Candiolo, Italy
11 INOC, Istituto Nazionale Oncologico Candiolo, IRCCS, Candiolo, Italy
12 INOC, Istituto Nazionale Oncologico Candiolo, IRCCS, Candiolo, Italy
13 INOC, Istituto Nazionale Oncologico Candiolo, IRCCS, Candiolo, Italy
14 Dana-Farber Cancer Institute, Boston, United States
15 Dana-Farber Cancer Institute, Boston, United States
16 Dana-Farber Cancer Insitute, Boston, United States
17 INOC, Istituto Nazionale Oncologico Candiolo, IRCCS, Candiolo, Italy
18 Dartmouth Hitchcock Medical Center, Lebanon, United States
19 Dana-Farber Cancer Institute, Boston, United States
20 Dana-Farber Cancer Institute, Boston, United States
21 INOC, Istituto Nazionale Oncologico Candiolo, IRCCS, Candiolo, Italy, University of Turin, Candiolo, Italy

RNA modifications constitute a dynamic layer of epitranscriptomic regulation that controls RNA splicing, stability, localization, translation, and decay, thereby shaping gene expression programs in normal physiology and disease. The most abundant internal RNA modification, N6-methyladenosine (m6A), is a major regulator of RNA metabolism and has emerged as a critical regulator of cancer biology. As the functional relevance of m6A-modified transcripts that sustain disease pathogenesis in multiple myeloma (MM) remains unknown, we evaluated the genome-wide landscape of m6A modification and then studied the drivers of these epitranscriptomic changes in MM.

We first generated an integrative, single-nucleotide-resolution m6A atlas by combining GLORI-seq and Oxford Nanopore direct RNA sequencing across newly-diagnosed primary patient samples (n=120) and MM cell lines (n=10). Preliminary analysis identified >30,000 individual m6A sites across >6,000 transcripts (60% protein-coding and 10-20% noncoding), with >85% of methylation events dependent on METTL3 activity. Analysis of the first 30 patient samples demonstrated broad conservation of m6A sites while enabling quantitative measurement of methylation stoichiometry.

METTL3 is the catalytic subunit of the complex that generates m6A modification on transcripts. We found that METTL3 was significantly overexpressed in 319 newly diagnosed MM patients compared with 16 normal plasma cell samples. High METTL3 expression was associated with inferior overall survival in the CoMMpass (HR 1.4, 95% CI 1.0-1.9, P=0.032) cohort. Consistent with these observations, genome-wide CRISPR-Cas9 screens identified METTL3 as one of the strongest genetic dependencies amongst m6A writer proteins. Pharmacologic inhibition of METTL3 with the small molecules METTL3 inhibitors STM2457 and STM3006 induced potent dose- and time-dependent anti-myeloma activity across number of MM cell lines (IC50 values ranging from 25-45µM and 2-7µM, respectively), and primary CD138+ MM cells (by 75% in ex vivo cultures containing CD138- bone marrow mononuclear cells), and significantly suppressed tumor growth in both subcutaneous H929 xenografts (by 73% at D14) and disseminated MOLP8-luc xenografts models (BLI reduction by 62% at D14).

To systematically distinguish functional m6A sites from passenger methylation events, we filtered the m6A-modified genes identified in our analysis using dependency maps for protein-coding genes and lncRNA isoforms. This integrative analysis identified essential m6A-modified transcripts required for MM survival, including established MM dependencies, such as IRF4 and MYC, together with tumor-essential lncRNAs carrying recurrent m6A modifications. Integration of GLORI-seq with CRISPR-Cas13 screening prioritized MALAT1, BCAN-AS2, and LINC02937 for functional validation based on their high METTL3-dependent methylation and their dependency for MM survival. Programmable CRISPR-dCas13-FTO epitranscriptomic editing selectively removed individual m6A marks from these lncRNAs, which significantly impaired MM cell viability. Mechanistically, demethylation redistributed MALAT1 away from chromatin, which is one of its major sites of activity, whereas demethylation of BCAN-AS2 and LINC02937 reduced their RNA stability. This establishes a direct causal role for m6A in regulating oncogenic lncRNA function.

Beyond tumor-essential transcripts, the atlas also identified clinically actionable immunotherapy targets, including BCMA, CD38, and GPRC5D, as conserved METTL3-dependent m6A-modified transcripts. These methylation events were confirmed by direct RNA sequencing in MM cell lines and primary patient samples. Functionally, METTL3 inhibition increased GPRC5D cell-surface expression, whereas inhibition of the m6A demethylase FTO reduced GPRC5D expression, identifying epitranscriptomic modulation as a potential strategy to enhance GPRC5D-directed immunotherapy.

In conclusion, here we establish the first transcriptome-wide, single-nucleotide-resolution m6A atlas of MM and demonstrate that METTL3-dependent m6A modifications affect therapeutically actionable protein-coding as well as lncRNA targets. This work provides a functional framework for discovering epitranscriptomic liabilities that can be exploited to target both intrinsic tumor dependencies and clinically relevant immunotherapy targets in MM.

Laure Vreux, PhD: No relevant conflicts of interest to declare.